The global TAM for treatment of diabetes is massive. US equity markets have a lot of experience valuing continuous glucose monitoring (CGM) device makers such as the market leader, Dexcom (NYSE; DXCM);
- The global TAM for CGM device makers is c. US$5bn with cagr c.11%.
- DXCM current mkt value = US$35bn, equating to a revenue multiple of about x35!!!
- The point is, US equity markets go bananas over diabetes treatment innovation due to huge TAM, cagr and IP protection.
For the treatment of DFU's;
- TAM of US$7bn and likely c.10% cagr
- The application of Synpath to DFU's is a sleeping giant under the sp of PNV.
- Forums
- ASX - By Stock
- Ann: First Patient enrolled - SynPath Diabetic Foot Ulcer Trial
The global TAM for treatment of diabetes is massive. US equity...
Featured News
Add PNV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.24 |
Change
-0.020(0.88%) |
Mkt cap ! $1.546B |
Open | High | Low | Value | Volume |
$2.26 | $2.27 | $2.23 | $2.045M | 909.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 39647 | $2.23 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.24 | 4080 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 32034 | 2.230 |
1 | 10000 | 2.220 |
5 | 45027 | 2.210 |
11 | 25706 | 2.200 |
2 | 7538 | 2.190 |
Price($) | Vol. | No. |
---|---|---|
2.260 | 20045 | 2 |
2.270 | 1321 | 1 |
2.280 | 3000 | 1 |
2.290 | 3849 | 1 |
2.300 | 41195 | 7 |
Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
Last
$2.25 |
  |
Change
-0.020 ( 0.46 %) |
|||
Open | High | Low | Volume | ||
$2.26 | $2.27 | $2.23 | 216364 | ||
Last updated 15.59pm 10/05/2024 ? |
Featured News
PNV (ASX) Chart |